NASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $242.15 +0.48 (+0.20%) Closing price 06/26/2026 03:59 PM EasternExtended Trading$244.70 +2.55 (+1.05%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Axsome Therapeutics Stock (NASDAQ:AXSM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Axsome Therapeutics alerts:Sign Up Key Stats Today's Range$238.25▼$247.5050-Day Range$182.72▼$255.1752-Week Range$96.09▼$260.19Volume7.35 million shsAverage Volume1.08 million shsMarket Capitalization$12.46 billionP/E RatioN/ADividend YieldN/APrice Target$258.95Consensus RatingModerate Buy Company Overview Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes. Axsome’s pipeline includes several late-stage and approved product candidates. AXS-05, a first-in-class oral investigational therapy combining dextromethorphan and bupropion, received U.S. Food and Drug Administration (FDA) approval for the treatment of major depressive disorder in 2021 and for agitation associated with Alzheimer’s disease. AXS-07, a combination of meloxicam and rizatriptan for acute migraine, gained FDA approval in 2023. The company is also advancing AXS-12 for narcolepsy and idiopathic hypersomnia under FDA review, as well as AXS-14, a proprietary formulation of esreboxetine, targeting fibromyalgia and related chronic pain conditions. Founded in 2012 and headquartered in New York City, Axsome Therapeutics conducts its research and development activities primarily in the United States. The company’s leadership team is led by President and Chief Executive Officer Herriot Tabuteau, M.D., who brings extensive experience in neurologic and psychiatric drug development. Under his guidance, Axsome has advanced multiple clinical programs through crucial regulatory milestones and continues to collaborate with academic institutions and contract research organizations to support its growth strategy.AI Generated. May Contain Errors. Read More Axsome Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreAXSM MarketRank™: Axsome Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 642nd out of 852 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingModerate Buy Consensus RatingAxsome Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 1 strong buy rating, 19 buy ratings, no hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Axsome Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($2.31) to $4.67 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -64.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -64.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 138.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.03% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.50 News SentimentAxsome Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Axsome Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 7 people have searched for AXSM on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat Follows9 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,666,006.00 in company stock.Percentage Held by Insiders20.60% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AXSM Stock News HeadlinesAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)June 26 at 7:10 AM | financialpost.comFAxsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)June 26 at 7:00 AM | globenewswire.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Analysts Offer Insights on Healthcare Companies: Immatics (IMTX) and Axsome Therapeutics (AXSM)June 18, 2026 | theglobeandmail.comRoger Jeffs Sells 286 Shares of Axsome Therapeutics (NASDAQ:AXSM) StockJune 12, 2026 | insidertrades.comInsider Selling: Axsome Therapeutics (NASDAQ:AXSM) Director Sells 300 Shares of StockJune 11, 2026 | insidertrades.comAxsome Therapeutics (NASDAQ:AXSM) CFO Nick Pizzie Sells 33,000 SharesJune 10, 2026 | insidertrades.comMark Coleman Sells 5,537 Shares of Axsome Therapeutics (NASDAQ:AXSM) StockJune 3, 2026 | insidertrades.comSee More Headlines AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $182.64 on January 1st, 2026. Since then, AXSM shares have increased by 32.6% and is now trading at $242.1460. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its earnings results on Monday, May, 4th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.41. The company's quarterly revenue was up 57.4% compared to the same quarter last year. Read the conference call transcript. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (1.69%), Bank of America Corp DE (1.16%), First Trust Advisors LP (1.12%) and Pictet Asset Management Holding SA (0.81%). Insiders that own company stock include Roger Jeffs, Nick Pizzie, Mark Coleman, Mark E Saad, Ari Maizel, Herriot Tabuteau, Mark L Jacobson and Hunter R Murdock. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Company Calendar Last Earnings5/04/2026Today6/29/2026Next Earnings (Estimated)8/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 AXSM's financial health is in the Green zone, according to TradeSmith. AXSM has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AXSM CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees380Year Founded2012Price Target and Rating Average Price Target for Axsome Therapeutics$258.95 High Price Target$380.00 Low Price Target$176.00 Potential Upside/Downside+6.9%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($3.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$183.17 million Net Margins-26.59% Pretax Margin-26.66% Return on Equity-267.16% Return on Assets-28.53% Debt Debt-to-Equity Ratio2.27 Current Ratio1.39 Quick Ratio1.32 Sales & Book Value Annual Sales$638.50 million Price / Sales19.52 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book138.37Miscellaneous Outstanding Shares51,460,000Free Float40,859,000Market Cap$12.46 billion OptionableOptionable Beta0.61 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:AXSM) was last updated on 6/29/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
